AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00299611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Tablets, dosage 500mg each tablet (1-4tablets/day)for 8 wks during the 2nd phase of the study.
Study NCT00299611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, No active ingredient, (1-4tablets/day) for 8 wks during the 2nd phase of the study.
Study NCT02922686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flucloxacillin
Description: One flucloxacillin capsule of 500mg strength taken four times daily for 7 days
Study NCT02922686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flucloxacillin
Description: One flucloxacillin capsule of 500mg strength taken four times daily for 7 days
Study NCT02922686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenoxymethylpenicillin
Description: One capsule of phenoxymethylpenicillin of 500 mg strength taken four times daily for 7 days
Study NCT02922686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for phenoxymethylpenicillin)
Description: Over-encapsulation of phenoxymethylpenicillin will be performed by the manufacturer of the investigational medicinal products such that placebo and active phenoxymethylpenicillin are identical in size, shape, colour and smell, and are packaged in identical bottles
Study NCT02809222 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: Blood samples
Study NCT02809222 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of life questionnaire
Description: Questionnaire to assess the quality of life of cancer patients
Study NCT03811236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: Two hours of mild cold exposure using a water-perfused vest
Study NCT02408757 — intervention group
Intervention type: PROCEDURE
Intervention: Sonographic monitoring
Description: Sonographic monitoring during weaning of cerebrospinal fluid drainage catheters
Study NCT02766556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: ISB with ropivacaine with dexmedetomidine or normal saline
Study NCT02766556 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISB
Description: ISB with ropivacaine with dexmedetomidine or normal saline
Study NCT02766556 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ISB
Description: ISB with ropivacaine with dexmedetomidine or normal saline
Study NCT02766556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: ISB with ropivacaine with dexmedetomidine or normal saline
Study NCT02766556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: ISB with ropivacaine with dexmedetomidine or normal saline
Study NCT03680846 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HF10 Therapy
Description: Senza 10 kHz Spinal Cord Stimulation
Study NCT03680846 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CMM
Description: Conventional Medical Management
Study NCT03680846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CMM
Description: Conventional Medical Management
Study NCT01051518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve System
Description: Transcatheter Aortic Valve
Study NCT01224951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone
Description: 400 microgram of beclomethasone will be given to the patients in arm 1. During the last 4 weeks, the patients will receive additional 400 microgram of Qvar.
Study NCT04301310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986235 (Treatment A)
Description: Specified dose on specified days
Study NCT04301310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin (Treatment B)
Description: Specified dose on specified days
Study NCT01985672 — intervention group
Intervention type: PROCEDURE
Intervention: Frozen embryo transfer
Description: Embryo transfer of frozen/thawed embryos after IVF/ICSI
Study NCT00006089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00006089 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT00923117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutent (sunitinib)
Description: Oral dose 37.5 mg daily on a continuous 4 week cycle
Study NCT02815839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Study NCT02815839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03060070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
Study NCT03060070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
Study NCT03060070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexmedetomidine
Description: dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
Study NCT03060070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
Study NCT04497051 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT-DSA
Description: CTA before and after embolization
Study NCT01389661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSV treatment
Description: Autologous maxillary bone marrow mesenchymal stem cells (MSV-H) collected from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV)
Study NCT01343381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hepalean Heparin
Description: 400 units per kilogram bolus prior to initiation of CPB
Study NCT01343381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPC Heparin
Description: 400 unit per kilogram bolus prior to initiation of CPB
Study NCT03753945 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI of the spine
Description: Perform a clinically indicated MRI of the spine in DBS patients
Study NCT02161900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yogic and routine exercises
Description: All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
Study NCT02161900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogic and routine exercises
Description: All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
Study NCT02194985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl 150 mg
Description: Migalastat HCl 150 mg (equivalent to 123 mg migalastat) was provided as capsules in blister packs. One capsule was taken orally every other day.
Study NCT04232618 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-biomarker point-of-care test
Description: Lateral flow device containing a combination of markers which have been shown to be associated with active tuberculosis.
Study NCT04038216 — intervention group
Intervention type: PROCEDURE
Intervention: Single-stage surgery
Description: the bone-anchored hearing implant will be inserted in one surgery
Study NCT04038216 — intervention group
Intervention type: OTHER
Intervention: Two-stage surgery
Description: Two-stage surgery has already been performed, data will therefore be retrospectively collected
Study NCT04072406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
Study NCT04072406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care packet
Description: Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
Study NCT02867644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Patients coming for preoperative breast assessment will have standard care.
Study NCT02867644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care + conversational hypnosis
Description: Patients coming for preoperative breast assessment will have standard care with conversational hypnosis
Study NCT00682578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin + Piperaquine (Artekin)
Description: An adult dose consists of four doses of two tablets, given at 0, 8, 24 and 48 h. The approximate total adult dose is 6/48 mg/kg (DHA/PPQ). For children, a dose of 1.6/12.8 mg/kg is given at the same time intervals; this dosage will be obtained by dissolving the tablets in 5 ml of water.
Study NCT00682578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artesunate-sulphadoxin/pyrimethamine, chloroquine
Description: The standard treatment will be in accordance with that in Afghanistan
Study NCT01676636 — intervention group
Intervention type: DRUG
Intervention: Traditional Tablet
Description: The traditional tablets will be swallowed with liquid. Each tablet will contain 500 mg of calcium (as calcium carbonate), thus participants will be asked to take 3 per day.. Participants will be asked to take the tablets with a liquid of their choosing with a meal. Traditional tablets will function as a control in this study, as they represent what is widely available on the market in Bangladesh.
Study NCT01676636 — intervention group
Intervention type: DRUG
Intervention: Chewable tablets
Description: Chewable tablets are chewed in the absence of additional water. Each chewable tablet will contain 300 mg of calcium (as calcium carbonate), thus participants will be asked to take 5 per day. Participants will be asked to consume the chewable tablets with a meal.
Study NCT01676636 — intervention group
Intervention type: DRUG
Intervention: Unflavoured Powder
Description: The unflavoured powder with suspension agent will be tasteless and consumed by either adding it to a semi-solid food or drink of one's choosing. Appropriate foods for mixing with the powder will be at the discretion of the participants. This vehicle was selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. A similar product is Sprinkles, a multiple micronutrient powder developed at SickKids by Dr. Zlotkin.
Study NCT01676636 — intervention group
Intervention type: DRUG
Intervention: Flavoured Powder
Description: The flavoured powder with suspension agent will be consumed by adding it to clean water with a meal. This vehicle was also selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. Similar products include oral rehydration salts or artificial juice flavour crystals.
Study NCT00891540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 0.5%
Study NCT00891540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 0.2%
Study NCT00891540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Isotonic NaCl
Study NCT00591318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone
Description: 2 grams of ceftriaxone given daily, Monday to Friday, excluding major holidays, for a total of 40 doses
Study NCT00591318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 50 cc of normal saline, daily, Monday through Friday, except for major holidays, for a total of 40 normal saline infusions.
Study NCT04431921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Functional capacity
Description: Six minute walk test used assessment of functional capacity. For respiratory function mouth pressures, for cognitive functions MoCA scale and for pain assessment pain threshold and tolerance test assessed.
Study NCT04694924 — intervention group
Intervention type: OTHER
Intervention: standard of care
Description: No other procedures than those performed during the usual care for prostate cancer patients will be done. No study medication will be provided as part of participation.~Clinical outcomes will be reported via predefined electronic forms, integrated into the electronic health record (EHR). Patient-reported outcomes will be collected electronically.~All treatment decisions will be made at the discretion of the investigator or treating physician.
Study NCT00856414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: 20U, up to two injections administered intramuscularly into the glabella (2 in each side of the corrugators and 1 in the procerus)
Study NCT01839604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: Intravenous infusion over 3 hours.
Study NCT04166799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepitel Film
Description: Mepitel® Film is a thin, soft and conformable transparent film dressing with Safetac®, offering protection for vulnerable skin.
Study NCT00647270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Pre-filled syringe. See arm for more detail
Study NCT00647270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pre-filled syringe. See arm for more detail
Study NCT00528554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser acupuncture
Description: laser acupuncture according to traditional chinese medicine criteria, energy dosage 1J/point, average of 8 points to be treated, once daily during chemotherapy course
Study NCT00528554 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo laser acupuncture
Description: laser acupuncture according to traditional chinese medicine criteria, average of 8 points to be treated, once daily during chemotherapy course
Study NCT04076098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline Hydrochloride
Description: Administration of Periocline gel into the periodontal pockets will be carried out until it overflows the pockets
Study NCT04076098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Minocycline Hydrochloride
Description: Administration of Periocline gel into the periodontal pockets will be carried out until it overflows the pockets
Study NCT02619383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: The treatment comprised 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
Study NCT00229515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: abciximab followed by implantation of bare metal stent
Description: Patients will receive infusion of abciximab at standard regimen before undergoing intervention for STEMI and then bare metal stent implantation in the culprit lesion
Study NCT00229515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abciximab and Sirolimus eluting stent
Description: Patients will receive abciximab infusion at standard regimen followed by implantation of sirolimus-eluting stent in the culprit lesion
Study NCT00229515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tirofiban and bare metal stent
Description: Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with bare metal stent implantation
Study NCT00229515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tirofiban and sirolimus-eluting stent
Description: Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with sirolimus-eluting stent implantation
Study NCT02135003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient-selected care buddy
Description: Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. Care buddies attended at least two HIV health education sessions similar to those provided to study participants. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments
Study NCT04139889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Confocal Laser Endomicroscopy
Description: Confocal laser microendoscopy (CLE) as a new non-invasive imaging technique can be used for optical biopsy, which can perform real-time microscopic information of tissue in vivo at cellular level with resolutions up to 1μm and magnifications up to 1000 times. CLE is now being increasingly used with very promising results in gastroenterology, especially in the diagnostic investigation of Barret's esophagus, stomach cancer, colorectal cancer and various lesions of the biliary tract. With an intravenous injection of fluorescein, probe-based CLE (pCLE: GastroFlex probe with the Cellvizio laser system, Mauna Technologies, Paris, France) allows us to view the interstitial spaces, cells, and small capillaries in a window of 240 μm and to a depth of 60 μm.
Study NCT04169932 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD20 CAR-T
Description: The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD20 CART cells per treatment course. The dose escalation test was designed to evaluate the four dose levels of CD20-CART (1 × 10 \^ 6 cells/kg,2 × 10 \^ 6 cells/kg,4 × 10 \^ 6 cells/kg,8 × 10 \^ 6 cells/kg).
Study NCT02720029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pH/impedance monitor
Description: Placement of pH/impedance monitor via the nasogastric route with monitoring for 24 hours, followed by removal.
Study NCT03236155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioid pain pills
Description: patient will receive their pain pill prescription
Study NCT02990624 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PUVA
Description: 36 sessions of psoralen-ultraviolet A, divided as 3 sessions weekly
Study NCT02704390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORADUR®-Methylphenidate
Description: ORADUR®-Methylphenidate is available in three dosage forms, 22 mg, 33 mg or 44 mg. Subjects will continue to receive ORADUR®-Methylphenidate at the previously determined optimal dose for 24 months.
Study NCT00388583 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Split, Inactivated, Trivalent Influenza Vaccine
Description: 0.1 mL, Intradermal
Study NCT00388583 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Split, Inactivated, Trivalent Influenza Vaccine
Description: 0.5 mL, Intramuscular
Study NCT02583217 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: To compare ketamine+propofol versus remifentanyl+propofol to maintain good laryngeal mask insertion conditions
Study NCT02583217 — intervention group
Intervention type: DRUG
Intervention: remifentanyl
Study NCT02583217 — intervention group
Intervention type: DRUG
Intervention: propofol
Study NCT00448097 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cetuximab
Description: No verifiable data available, PI relocated
Study NCT00448097 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Description: No verifiable data available, PI relocated
Study NCT00463606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335 and rosuvastatin calcium
Description: ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks
Study NCT00463606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks
Study NCT00463606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin calcium
Description: Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks
Study NCT01922648 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.
Study NCT02707653 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol
Description: 400 mcg sublingual misoprostol
Study NCT04040348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Approximately 100 million cells allogeneic hMSC
Description: Umbilical cord-derived, allogeneic hMSC administered intravenously at a dose of approximately 100 million cells per infusion.